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Understanding how tumor cells invade tissues is key to developing drugs to block metastasis. In 
this issue, Muller et al. (2009) report that a mutant form of the tumor suppressor p53 in cancer cells 
boosts the endocytic recycling of the adhesion molecule integrin α5β1 and of epidermal growth 
factor receptor, promoting invasion and metastasis.Metastasis—the ability of cells in a pri-
mary tumor to invade other tissues and 
to spread throughout the body—is the 
underlying cause of most cancer deaths. 
Myriad cellular signaling pathways are 
known to facilitate tissue invasion and 
metastasis (Chiang and Massagué, 
2008). Many of these pathways are 
highly cell type and context dependent 
and so may drive metastasis of only a 
few tumor types. Hence, pinpointing sig-
naling pathways that facilitate the metas-1220 Cell 139, December 24, 2009 ©2009 Etasis of many types of tumors would 
provide valuable targets for preventing 
the spread of many different cancers. 
Inactivation of the tumor suppressor 
protein p53 through point mutations or 
enhanced degradation of the protein is 
a trait common to the majority of human 
cancers. In this issue of Cell, Muller et al. 
(2009) show both in vitro and in vivo that 
expression of mutant p53 drives invasion 
and metastasis through increased recy-
cling of integrins and epidermal growth lsevier Inc.factor receptor (EGFR) back to the 
plasma membrane of tumor cells. They 
further demonstrate that the ability of 
mutant p53 to drive invasion correlates 
with its sequestration of p63, a transcrip-
tion factor and p53 family member.
Given that mutant p53 is frequently 
overexpressed in many tumors (Seli-
vanova and Wiman, 2007), a key ques-
tion that has puzzled cancer research-
ers is why tumors retain this disabled 
tumor suppressor rather than losing it Figure 1. Mutant p53 and Tumor Metastasis
A mutant form of the tumor suppressor protein p53 sequesters p63 (a transcription factor and p53 family member) and blocks its transcriptional activity. This 
could result in altered expression (red cross) of as yet unknown factors (?) that normally would block the endocytic recycling of the adhesion molecule α5β1-
integrin and epidermal growth factor receptor (EGFR). Thus, sequestration of p63 indirectly results in enhanced targeting of α5β1 and EGFR (in a complex with 
Rab-coupling protein, RCP) back to the plasma membrane. An increase in α5β1-integrin and EGFR at the tumor cell surface boosts the phosphorylation and 
activation of Akt kinase, which correlates with an increase in the metastatic potential of these cells.
entirely, as is the case with other tumor 
suppressors such as the retinoblastoma 
protein or p16. Compelling experimen-
tal evidence from mouse models sug-
gests that mutant p53 acquires a gain 
of function that imbues tumor cells with 
increased capabilities for invasion and 
metastasis that are not seen in mice 
that have lost both p53 alleles (Brosh 
and Rotter, 2009). Furthermore, in many 
types of human tumors, overexpres-
sion of mutant p53 is associated with a 
poor prognosis, supporting the idea of a 
gain-of-function phenotype for mutant 
p53, rather than a loss-of-function or 
dominant-negative effect of wild-type 
p53 (Brosh and Rotter, 2009). Mutant 
p53 perturbs the expression of multiple 
genes through abnormal binding to DNA 
or to proteins, such as the transcription 
factors NF-κB and E2F1 and the p53 
family members p63 and p73 (Brosh and 
Rotter, 2009). Sequestration of p63 by 
mutant p53 appears to play a key role 
in promoting invasion and metastasis 
through several mechanisms. Muller et 
al. (2009) now describe a novel twist in 
this mutant p53 gain-of-function story 
with their report of a new link between 
the intracellular trafficking of key mol-
ecules involved in adhesion and invasion 
(integrins and EGFR) and the inactivation 
of p63 by mutant p53.
Loss of one p63 allele weakens the 
ability of wild-type p53 to carry out its 
transcriptional function and imbues 
tumors lacking one wild-type p53 allele 
(p53+/−) with metastatic properties. In 
contrast, in tumors overexpressing 
mutant p53 rather than losing expres-
sion of wild-type p53, the interaction of 
mutant p53 with p63 drives the meta-
static phenotype (Brosh and Rotter, 
2009). Notably, transcriptional profiling 
has revealed that p63 regulates a whole 
axis of cell adhesion molecules, includ-
ing laminin-binding integrins (α3β1, 
α6β1, α6β4) and a variety of integrin 
subunits (α5, β1), which bind to fibronec-
tin in the extracellular matrix (Carroll et 
al., 2006). Recent work has shown that 
in the presence of mutant p53, p63 
and p73 drive expression of β4-integrin 
resulting in increased invasion capabili-
ties and activation of Akt kinase (Bon et 
al., 2009). Mutant p53 may switch the 
p63 transcriptional program over to a 
tumor-promoting profile by inducing the expression of integrins and increasing 
their recycling in endosomes back to the 
cell surface. Muller and colleagues now 
demonstrate an absolute requirement for 
α5β1-integrin and EGFR in the invasion 
ability of tumor cells in vitro. The fact that 
they did not observe notable changes in 
the expression of integrin α5β1, EGFR, 
or the Rab-coupling protein (RCP, which 
facilitates endocytic recycling) suggests 
that enhanced endocytic trafficking of 
these factors (rather than transcriptional 
control of integrin expression) is the main 
mechanism for driving tumor invasion in 
this model.
Muller and coworkers extend these 
findings and show that mutant p53 
facilitates tissue invasion by tumor cells 
by boosting the interaction between 
RCP and α5β1-integrin and the endo-
cytic recycling of α5β1 and EGFR. They 
demonstrate that exogenously intro-
duced and endogenously expressed 
mutant p53 in several cell lines drives 
invasion in assays in vitro and confirm 
this finding in immunocompromised 
mice transplanted with human tumor 
cell xenografts. Further, in mice lacking 
the Apc tumor suppressor, expression 
of mutant p53 increases invasiveness of 
intestinal tumor cells by 75%. In cell cul-
ture assays, enhanced formation of the 
α5β1-EGFR-RCP complex augments the 
random motility of tumor cells and their 
ability to invade fibronectin-containing 
matrices and correlates with increased 
phosphorylation of Akt kinase (Figure 1). 
Consistent with this, the authors dem-
onstrate a correlation between mutant 
p53 expression and Akt phosphoryla-
tion in human tumor samples.
The endocytic trafficking of inte-
grins back to the plasma membrane 
regulates many adhesion-dependent 
processes. These include cell motil-
ity, cytokinesis, and the interaction 
between integrins and growth factor 
receptors that controls the signaling 
pathways that induce tumor cell pro-
liferation and invasion (Caswell et al., 
2009). Importantly, trafficking of dif-
ferent integrin heterodimers is highly 
interconnected and regulates the rate 
of recycling of other receptors to the 
plasma membrane, including EGFR 
and vascular epidermal growth factor 
receptor (VEGFR). In fibroblasts, cancer 
cells, and endothelial cells, the recog-Cell 139, Denition of ligand by ανβ3-integrin and its 
rapid endocytic recycling suppresses 
formation and recycling of a complex 
comprising RCP, α5β1-integrin, and 
EGFR or VEGFR2 (Caswell et al., 2009). 
Interestingly, small-molecule inhibitors 
designed to block ανβ3-integrin during 
blood vessel formation (angiogenesis) 
also seem to induce tumor metastasis 
by boosting the recycling of the α5β1-
EGFR-(or VEGFR2)-RCP complex (Cas-
well et al., 2009).
Recent in vitro and in vivo data chal-
lenge the view that ανβ3-integrin is a 
tumor promoter and instead suggest 
a potential inhibitory role for ανβ3-
integrin in tumor metastasis. Over-
expression of ανβ3-integrin in ovar-
ian tumor cells result in a decrease in 
tissue invasion in vitro, and patients 
with ovarian carcinoma whose tumors 
overexpress β3-integrin have a sig-
nificantly better prognosis (Kaur et 
al., 2009). These data underscore the 
clinical relevance of work describing 
ανβ3-integrin as a major inhibitor of the 
recycling of the α5β1-EGFR-RCP com-
plex and hence of tumor metastasis. 
From a therapeutic viewpoint, the new 
work by Muller et al. together with pre-
vious reports raise the possibility that 
tumors expressing mutant p53 may be 
eradicated efficiently by blocking the 
proinvasion gain-of-function effects 
of mutant p53. This could be achieved 
either by molecules directly disrupt-
ing the interaction of mutant p53 with 
p63 or by restoring mutant p53 to its 
wild-type conformation (Selivanova 
and Wiman, 2007). Yet it is still unclear 
how increased endocytic recycling of 
integrins is achieved. Does mutant p53 
block p63 transactivation or induce 
abnormal activity of p63? Which tar-
gets of p63 directly regulate the recy-
cling of integrins? Further experiments 
with different in vitro assays of tumor 
cells and their interactions with extra-
cellular matrix molecules will hopefully 
define the critical integrin-mediated 
pathways that are activated in cells 
harboring p53 point mutations.
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Like good housekeepers, cells spend 
considerable energy caring for their 
genetic material, mopping up DNA 
damage that may alter the reading of 
their genetic information. The most dif-
ficult type of damage to repair, and at 
the same time the most detrimental, 
are DNA interstrand crosslinks (ICLs). 
ICLs block DNA replication, making 
their removal an essential requirement 
for cell survival. Defects in ICL repair 
underlie Fanconi Anemia (FA), and the 
severe clinical symptoms of the disorder 
(blood marrow failure, developmental 
abnormalities, and cancer predisposi-
tion, often leading to an early death) tes-
tify to the toxicity of ICLs (Moldovan and 
D’Andrea, 2009; Patel and Joenje, 2007). 
Yet, how the proteins in the FA pathway 
protect against ICLs has long remained a 
mystery. Using a cell-free system, Knip-
scheer et al. (2009) now show that FA 
proteins are directly involved at several 
steps in the process of ICL repair.
Removal of ICLs mostly occurs in 
S phase and involves the stepwise 
involvement of nucleases, specialized 
DNA polymerases that bypass lesions, 
and factors that mediate homologous 
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recombination (Moldovan and D’Andrea, 
2009). In prior work the authors devised 
an experimental approach to investigate 
replication-dependent repair of ICLs 
using a cell-free replication system of egg 
extracts from the frog Xenopus (Raschle 
et al., 2008). Their system reveals that 
replication forks, converging from both 
directions, initially stop 20–40 nucle-
otides from the crosslink (Figure 1). One 
of the forks subsequently moves further 
and stops again just before the crosslink 
(at position −1). Nucleolytic incisions on 
both sides of the crosslink, and DNA 
polymerization across the lesion, restore 
one of the chromatids, whereas the other 
chromatid is most likely repaired through 
homologous recombination. In an ele-
gant application of their crosslink repair 
system, Knipscheer et al. now show 
that loss of proteins in the FA pathway 
can block both the incision and bypass 
steps.
Thirteen proteins cooperate in the FA 
pathway. Eight of these proteins form a 
ubiquitin ligase complex that monou-
biquitinates the substrates FANCD2 and 
FANCI. In the new study, immunodeple-
tion of FANCD2 from the egg extracts 
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gene 26, 2243–2254.(which also codepletes its heterodimeric 
partner FANCI) dramatically inhibits 
crosslink repair, demonstrating that FA is 
a true DNA repair syndrome. Nucleotide 
insertion opposite the ICL is blocked in 
the absence of FANCD2, such that the 
leading strand progresses only to posi-
tion −1. Also, the two incisions required 
to unhook the crosslink are not detected 
in extracts depleted of FANCD2. All 
defects can be rescued by adding back 
the recombinant FANCD2-FANCI com-
plex, but not by adding back a complex 
containing a point mutant of FANCD2 
that cannot be ubiquitinated. Accord-
ingly, when the investigators examine the 
timing of FANCD2 ubiquitination, they 
find that this modification occurs pre-
cisely when the replication fork reaches 
the −1 position. FANCD2 ubiquitination, 
known to be essential for crosslink tol-
erance, is therefore required to advance 
the replication fork across the crosslink, 
by orchestrating the unhooking of the 
crosslink and DNA synthesis across the 
lesion.
Bypass of DNA lesions is a poten-
tially mutagenic process performed by 
specialized polymerases. The FA path-
strand 
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